Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

C023 - Dermatology Review: General Dermatology and Practice Management

Sunday, February 18; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize new developments in general dermatology.
  • Analyze and describe best practices for practice management, coding, and electronic health records.
  • Evaluate new treatment options for dermatologic conditions, including acne, rosacea, psoriasis, and eczema.


This course will comprehensively review new developments in medical, cosmetic and surgical dermatology. Innovation in diagnosis and treatment of common dermatologic conditions, such as skin cancer, actinic keratosis, psoriasis, eczema, acne, contact dermatitis, infectious diseases in dermatology, and rosacea will be reviewed. New developments in cosmetic dermatology and best practices in surgical and cosmetic dermatology will be reviewed. Practice management, including billing, coding, electronic health records, and new payment models.


  • Berman, Brian, MD, PhD: Aclaris Therapeutics, Inc. – A(H), C(H); Actavis – I(Grants/Research Funding); AiViva BioPharma, Inc. – C(H); Allergan, Inc. – I(Grants/Research Funding); Allos – A(H); Almirall – A(H); Amira Pharmaceuticals – C(H); Anacor Pharmaceuticals, Inc. – A(H), I(Grants/Research Funding); Bayer Pharmaceuticals – SP(H); Berg Pharma, LLC – A(ST), C(H); Biofrontera AG – C(H), I(Grants/Research Funding); BirchBioMed – A(H); C & H Scientific, LLC – A(H); Capstone Therapeutics Corp. – C(H); Celumigen Pharmaceuticals, Inc. – B(SO), C(H), C(SO); Centocor Ortho Biotech Inc. – C(H), SP(H); CHS Pharma – A(ST); Clark Pharmaceuticals, LLC – C(H); Crescita Therapeutics Inc. – C(H); Cutanea Life Sciences – A(H); Dermira – A(H); Doak – A(H); Dr. Tattoff – A(H), A(SO); DUSA Pharmaceuticals, Inc – A(H); DUSA Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding); Encore Dermatology, Inc. – I(Grants/Research Funding); Excaliard Pharmaceuticals, Inc. – C(H); Exeltis – C(H), I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – C(H); Graceway Pharmaceuticals, LLC – SP(H); Halscion – A(H); IntraDerm Pharmaceuticals – A(H), C(H); Klara/Goderma, Inc. – C(SO); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – A(H), SP(H); Liquidia Technologies, Inc. – C(H); Medicis Pharmaceutical Corporation – A(H), SP(H); Medimetriks Pharmaceuticals, Inc. – C(H); MediWound – C(H); Menlo Therapeutics – A(H), I(Grants/Research Funding); Merz Pharmaceuticals, LLC – A(H), Speaker/Faculty Education(H); miRagen Therapeutics, Inc. – C(H), I(Grants/Research Funding); Novan – C(H); Novartis Pharmaceuticals Corp. – SP(H); Oculus innovative Sciences, Inc. – C(SO); Onset Therapeutics – A(H), SP(H); Peplin Inc. – A(H), C(H); Pharmaderm – A(H); Pulse Biosciences – C(H); Realm Therapeutics – C(H); RXi Pharmaceuticals Corporation – I(NC); sanofi-aventis – A(H), SP(H); Seattle Genetics – A(H); Sensus Healthcare – A(H), SP(H); Sirnaomics, Inc. – C(H); Smith & Nephew – A(H); Sol-Gel Technologies – C(H); Sonoma Pharmaceuticals – C(SO); Stiefel a GSK company – A(H), SP(H); Tigercat Pharma, Inc – I(Grants/Research Funding); TopMD – A(ST), C(H); Valeant Pharmaceuticals International – SP(H);
  • Goldenberg, Gary, MD: AbbVie – SP(H); Allergan, Inc – C(H); Anacor Pharmaceuticals, Inc. – C(H); Bayer – SP(H); Bayer Pharmaceuticals – C(H); Castle Biosciences – SP(H); Celgene Corporation – C(H), SP(H); Dermira – A(H); Eclipse Medical – C(H); Eli Lilly and Company – C(Fees), SP(H); Galderma USA – SP(H); Genentech, Inc. – C(H); Janssen Pharmaceuticals, Inc – C(H); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – C(H), SP(H); MelaSciences – C(H); Novartis Pharmaceuticals Corp. – C(H), SP(H); Pfizer Inc. – C(H); Pharmaderm – A(H), I(Grants/Research Funding), SP(H); Ranbaxy Laboratories Limited – C(H); Stiefel a GSK company – C(H), I(Grants/Research Funding); Taro Pharm – C(Fees); Teva Pharmaceuticals USA – C(Fees); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding), SP(H); Xoft – C(H);
  • Green, Lawrence J., MD: AbbVie – SP(H); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Amgen – SP(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Cassiopea S.p.A. – C(NC); Celgene – A(H), I(Grants/Research Funding); Celgene Corporation – SP(H); Demira – A(H), SP(H); Dermira – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Leo Pharma Inc. – SP(H); Merz Aesthetics – A(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding), SP(H); Ortho Dermatologics – SP(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – SP(H); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding); ZO Skin Health, Inc. – C(H);
  • Kaufmann, Mark D., MD: Almirall – C(Fees); BioPharmX – C(Fees); Cutanea Life Sciences – C(Fees); Dermira – C(Fees); IntraDerm Pharmaceuticals – C(Fees); ISDIN – C(Fees); Klara/Goderma, Inc. – C(SO); L'Oreal USA Inc. – C(Fees); La Roche-Posay Laboratorie Pharmaceutique – C(Fees); Menlo Therapeutics – C(Fees); Modernizing Medicine – C(SO); MoleSafe, Inc. – O(Fees), O(ST); Ortho Dermatologics – C(Fees); Pfizer Inc. – C(Fees); Promius Pharma, LLC – C(Fees); SciBASE – C(Fees); Sun Pharmaceutical Industries Ltd. – C(Fees); UCB – C(Fees);
  • Kircik, Leon H., MD: 3M Pharmaceuticals – I(Grants/Research Funding), SP(H); Abbott Laboratories – SP(H); Ablynx – I(Grants/Research Funding); Acambis – I(Grants/Research Funding); Allergan, Inc – A(H), C(H), I(H), SP(H); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding), SP(H); AnaptysBio – I(Grants/Research Funding); Aqua – A(H); Astellas Pharma US, Inc – I(Grants/Research Funding), SP(H); Asubio Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Biogen – A(H); Biolife – I(Grants/Research Funding); Biopelle, Inc. – I(Grants/Research Funding); Breckinridge Pharma – I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); ColBar LifeScience Ltd. – A(H), C(H); CollaGenex Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding), SP(H); Connetics Corporation – A(H), C(H), I(Grants/Research Funding); Coria Laboratories – I(Grants/Research Funding); Dermik Laboratories, a business of sanofi-aventis U.S. LLC – SP(H); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Embil Pharmaceuticals, Co., Ltd – SP(H); EOS – A(H); Ferndale Laboratories, Inc. – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – A(H), C(H), I(Grants/Research Funding); Isdin – A(H); Johnson & Johnson Consumer Products Company – A(H), C(H), I(Grants/Research Funding), SH(ST), SP(H); Laboratory Skin Care, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding), SP(H); Medical International Technologies – C(H); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc – C(H); Merck Serono – SP(H); Merz Pharmaceuticals, LLC – C(H); NanoBio Corporation – A(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Nucryst – I(Grants/Research Funding); Obagi Medical Products – I(Grants/Research Funding); Onset Dermatologics – I(Grants/Research Funding), SP(H); Othro Dermatologics – A(H), C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – I(Grants/Research Funding); Pharmaderm – I(Grants/Research Funding), SP(H); Promius Pharma, LLC – A(H), C(H), I(Grants/Research Funding); PuraCap Pharmaceutical – C(H); QLT Inc. – I(H); SkinMedica, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); Stiefel a GSK company – A(H), C(H), I(Grants/Research Funding), SP(H); Sun Pharmaceutical Industries Ltd. – A(H), SP(H); Taro Pharm – C(H), I(Grants/Research Funding); TolerRx – I(Grants/Research Funding); Triax Pharmaceuticals, LLC – C(H), I(Grants/Research Funding), SP(H); Valeant Pharmaceuticals International – A(H), C(H), I(Grants/Research Funding), SP(H); Warner Chilcott – A(H), I(Grants/Research Funding), SP(H); Xenoport, Inc. – I(Grants/Research Funding); Zalicus – I(Grants/Research Funding);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Lober, Clifford Warren, MD, JD: no financial relationships exist with commercial interests.
  • Rosen, Theodore, MD: Medimetriks Pharmaceuticals, Inc. – C(H); Menlo Therapeutics – A(H); Valeant Pharmaceuticals International – C(H);
  • Siegel, Daniel M., MD, MS: Actavis – I(Grants/Research Funding); Allergan, Inc – A(H); Athenex – A(H); Biofrontera AG – A(H), SH(ST); Caliber Imaging and Diagnostics Inc. – B(SO); Clearpath Solutions Group – A(H); Dantech Systems – F(IP); DermTech International – A(SO); Elsevier Inc. – O(IP); Ferndale Laboratories, Inc. – A(H); Fiorello Pharmaceuticals, Inc. – B(NC), SH(NC); Galderma Laboratories, L.P. – A(H); Genentech, Inc. – SP(H); Kamedis Limited – A(Fees), C(ST); Klara/Goderma, Inc. – A(SO); LEO Pharma, US – A(H), C(H); Logical Images – C(SO); MedX Health – C(NC); Menlo Therapeutics – A(H); Modernizing Medicine – A(SO); Novascan – SH(NC); Or-Genix, Therapeutics – B(SO); Pfizer Inc. – A(H); Photomedex – A(ST); RaMedical – SH(NC); Regeneron – I(Grants/Research Funding); SciBASE – C(NC); SkinVision – A(SO); SPC Dermatology – C(S); Strata Skin Sciences – C(Fees); Sun Pharmaceutical Industries Ltd. – A(H); Tetros Group – A(NC); Valeant Pharmaceuticals International – C(Fees); Valeant Pharmaceuticals North America LLC – A(H);
  • Stein Gold, Linda F., MD: AbbVie – A(H); Actavis – SP(H); Allergan, Inc. – I(Grants/Research Funding); Aqua – A(H); Ferndale Laboratories, Inc. – C(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – A(H); Leo Pharma Inc. – I(Grants/Research Funding); LEO Pharma, US – A(H); Lilly ICOS LLC – A(H); Medicis Pharmaceutical Corporation – A(H); Merz Pharmaceuticals, LLC – A(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Promius Pharmaceuticals – A(H); Roche Laboratories – Independent Contractor(Fees), O(H); Sol-Gel Technologies – C(Grants/Research Funding); Stiefel a GSK company – A(H); Taro Pharm – A(H), C(H); Topica – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), I(Grants/Research Funding);
  • Tomecki, Kenneth J., MD: no financial relationships exist with commercial interests.
Sunday, February 18
1:00 PM
Dr. Lober / Update on MACRA, MIPS, and APMs
1:15 PM
Dr. Kaufmann / Update on Electronic Health Records
1:30 PM
Dr. Tomecki / Vaccines in dermatology
1:45 PM
Dr. Berman / Control of Post-Surgical Scarring and Keloids
2:00 PM
Dr. Stein Gold / Treatment of acne in 2018
2:15 PM
Dr. Lober, Dr. Tomecki, Dr. Berman, Dr. Stein Gold, and Dr. Kaufmann / Q&A
2:30 PM
Dr. Green / Rosacea update
2:45 PM
Dr. Siegel / ICD-10 Update
3:00 PM
Dr. Lebwohl / Treatment pearls for psoriasis and eczema
3:15 PM
Dr. Kircik / How to correct your common coding mistakes
3:30 PM
Dr. Rosen / STD's in 2018 - What's New
3:45 PM
Dr. Siegel, Dr. Rosen, Dr. Lebwohl, Dr. Kircik, and Dr. Green / Q&A
Event Details
  • Date
    Sunday, February 18
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 8
  • CME Credits
  • Type
    Practice Management
  • Gary Goldenberg, MD, FAAD
  • Brian Berman, MD, PhD, FAAD
  • Clifford Warren Lober, MD, JD, FAAD - Handout
  • Daniel M. Siegel, MD, MS, FAAD - Handout
  • Kenneth J. Tomecki, MD, FAAD
  • Lawrence J. Green, MD, FAAD - Handout
  • Leon H. Kircik, MD, FAAD - Handout 1, Handout 2, Handout 3
  • Linda F. Stein Gold, MD, FAAD
  • Mark D. Kaufmann, MD, FAAD - Handout
  • Mark Lebwohl, MD, FAAD - Handout
  • Theodore Rosen, MD, FAAD - Handout